Literature DB >> 7517377

BPH: new guidelines based on symptoms and patient preference. The Agency for Health Care Policy and Research.

R G Roberts1.   

Abstract

Benign prostatic hyperplasia (BPH) is the most common tumor in the aging human male. BPH is rarely a life-threatening condition, but it can affect the quality of an older man's life when it causes urinary symptoms. Several interventions are available for BPH: surgery, most often transurethral resection of the prostate (TURP); medication, including alpha blockers and 5-alpha reductase inhibitors; and balloon dilation. An appropriate option for many men is no active treatment but "watchful waiting." The common nature and cost of BPH and the range of available therapies stimulated the development of a guideline by a multidisciplinary panel sponsored by the federal Agency for Health Care Policy and Research (AHCPR).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517377

Source DB:  PubMed          Journal:  Geriatrics        ISSN: 0016-867X


  4 in total

1.  Underdetection of clinical benign prostatic hyperplasia in a general medical practice.

Authors:  M F Collins; R H Friedman; A Ash; R Hall; M A Moskowitz
Journal:  J Gen Intern Med       Date:  1996-09       Impact factor: 5.128

Review 2.  Tamsulosin: an update of its role in the management of lower urinary tract symptoms.

Authors:  Katherine A Lyseng-Williamson; Blair Jarvis; Antona J Wagstaff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.

Authors:  Christopher J Dunn; Anna Matheson; Diana M Faulds
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

4.  Diagnosis and treatment of benign prostatic hyperplasia. Practice patterns of primary care physicians.

Authors:  M M Collins; M J Barry; L Bin; R G Roberts; J E Oesterling; F J Fowler
Journal:  J Gen Intern Med       Date:  1997-04       Impact factor: 5.128

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.